In this presentation, Richard Meinesz, R&D Advisory at Syneos Health, shares a crucial session on managing expectations for successful AI implementation in pharma and healthcare.

Are you struggling to translate AI excitement into tangible results? Frustrated by promising POCs that never scale? This presentation cuts through the hype to deliver practical wisdom on bridging the gap between AI's immense potential and real-world implementation challenges.

Download to learn more about:

• Why expectation management is the critical factor in successful AI development
• How to navigate the common pitfalls that prevent 85% of AI initiatives from delivering ROI
• Practical strategies to transform product development teams from "buzzkills" to innovation enablers
  

AI is revolutionising every facet of the life sciences – from drug discovery to diagnostics, patient engagement to operational efficiency, with funding for AI-focused digital health companies having surged from 7% in 2015 to 42% in 2024.

Our latest report, The Pharma AI Revolution: The Breakthrough Technologies Reshaping Healthcare, is your definitive playbook to understanding how artificial intelligence is shaping the future of pharma and healthcare. Built on deep industry analysis, real-world case studies, and expert insights, this guide empowers decision-makers to cut through the noise and make smarter investments in AI-driven innovation.

Download to learn more about:

• Industry-wide analysis of AI’s most transformative applications
• Decision-making frameworks and maturity scores for top AI technologies
• Practical takeaways, checklists, and use cases to guide your next move
  

Artificial Intelligence in pharma and healthcare has crossed the threshold of experimentation, delivering real-world impact at scale. The question is no longer whether AI works, but how quickly and effectively it can be integrated across the value chain.

From accelerating drug discovery and optimising trial design to transforming commercial models and improving patient engagement, AI is becoming the backbone of next-generation healthcare systems. This smart summary distils the most critical insights into one powerful piece, built to help decision makers cut through the noise and focus on what matters. With exclusive insights from Rajvir Madan, Chief Digital and Information Technology Officer, Arcutic Biotherapeutics, this guide provides a clear, strategic snapshot of where AI is delivering value and how to stay ahead of the curve.

Download to learn more about:

• Where AI is delivering tangible value today: Across R&D, clinical development, and commercial operations
• The biggest implementation challenges: From data quality and regulatory compliance to change management
• A roadmap for adoption at scale: Including steps to operationalise AI responsibly and ethically

AI’s role in healthcare is no longer about potential, it’s about performance. With the industry under pressure to innovate faster, deliver more personalised care, and improve cost-efficiency, the strategic deployment of AI has become a competitive advantage. This infographic brings together the key drivers, challenges, and enablers that every pharma and healthcare leader needs to understand today.

The advent of Artificial Intelligence (AI) has initiated a transformative wave across various industries, with the pharmaceutical sector standing at the forefront of this technological revolution. In the pharmaceutical industry, AI is not just a tool but a catalyst reshaping drug discovery, clinical trials, supply chain, and manufacturing. Understanding the impact, implementation challenges, and future potential of these evolving technologies is essential for industry stakeholders.

AI has massive potential across the entire pharmaceutical value chain and the broader healthcare industry. This report will drill down into some of the most exciting opportunities within the pharmaceutical value chain, including drug discovery and development, clinical trials, manufacturing, and supply chain management—key segments where AI is driving significant advancements.

Dive into an exclusive preview of the content below and enter details to receive the full copy

Introduction:

The advent of Artificial Intelligence (AI) has initiated a transformative wave across various industries, with the pharmaceutical sector standing at the forefront of this technological revolution. In the pharmaceutical industry, AI is not just a tool but a catalyst reshaping drug discovery, clinical trials, supply chain, and manufacturing. Understanding the impact, implementation challenges, and future potential of these evolving technologies is essential for industry stakeholders.

AI has massive potential across the entire pharmaceutical value chain and the broader healthcare industry. This report will drill down into some of the most exciting opportunities within the pharmaceutical value chain, including drug discovery and development, clinical trials, manufacturing, and supply chain management—key segments where AI is driving significant advancements

Learn how AI enhances target identification, lead optimization, data integration, predictive analytics, and automation. Discover case studies from BenevolentAI, AstraZeneca, and more. Connect with industry leaders and innovators. Enhance your R&D processes and maximize ROI with cutting-edge AI applications.

The EU AI Act is a comprehensive regulation designed to ensure AI systems are safe, transparent, and respectful of fundamental rights. It categorises AI systems based on their risk levels—ranging from minimal risk to high risk—and establishes specific requirements for each category. For the pharmaceutical and healthcare industries, this means greater scrutiny, enhanced data quality, robust compliance frameworks, and significant operational adjustments. As the industry increasingly relies on AI for drug discovery, clinical trials, and patient care, understanding and adapting to the EU AI Act is crucial for compliance and innovation. This guide to the EU AI Act will ensure that you understand how to prepare for its full implementation while remaining at the forefront of innovation.

Dive into an exclusive preview of the content below and enter details to receive full copy

Introduction:

The EU AI Act represents a significant regulatory development aimed at harmonising rules for Artificial Intelligence (AI) within the European Union. This legislation is designed to address the risks associated with AI, ensuring its safe and ethical deployment. For the pharmaceutical and healthcare sectors, understanding the implications of the AI Act is crucial, given the industry’s increasing reliance on AI for drug discovery, clinical trials, and patient care.

What is the EU AI Act?

The EU AI Act is a comprehensive regulation designed to ensure AI systems are safe, transparent, and respectful of fundamental rights. It categorises AI systems based on their risk levels—ranging from minimal risk to high risk—and establishes specific requirements for each category.

High-risk AI systems, such as those used in healthcare, must comply with stringent standards to mitigate potential harms and biases. AI systems that present unacceptable risks, such as real-time biometric identification in public spaces, are banned outright (DW, 2024) (Reed Smith LLP, 2024).

To read more, including an implementation timeline, enter your details below. 

Discover how Artificial Intelligence (AI) is revolutionising pharmaceutical supply chains, enhancing operational efficiencies from raw material sourcing to final product delivery. This infographic delves into the key areas where AI is making a significant impact, including demand forecasting, regulatory compliance, and risk management. Download to explore real-world applications and the actionable steps companies can take to seamlessly integrate AI.

Rajvir Madan, Chief Digital and Information Technology Officer, Arcutis Biotherapeutics, shares his groundbreaking session on harnessing the power of AI in pharmaceutical innovation at the AI in Pharma & Healthcare Summit 2024.

This compelling case study, Raj Madan demonstrates how AI tools can systematically identify new drug development opportunities, repurpose existing targets, and create a comprehensive therapeutic landscape, all while validating what you already know and revealing what you don't. This session isn't about hypothetical AI potential, it's about actionable implementation that delivers measurable results for R&D and Business Development teams today.

Artificial Intelligence (AI) is transforming the landscape of clinical trials, significantly enhancing patient recruitment and retention processes. This article explores how AI is being utilised to improve these critical aspects of clinical trials, ensuring more efficient, cost-effective, and successful outcomes.